|4Jun 20, 8:56 PM ET

Campbell Wendy Pizarro 4

4 · Calidi Biotherapeutics, Inc. · Filed Jun 20, 2024

Insider Transaction Report

Form 4
Period: 2024-06-17
Transactions
  • Award

    Stock Options (right to buy)

    2024-06-17+60,00060,000 total
    Exercise: $0.20Exp: 2034-06-17Common stock (60,000 underlying)
  • Award

    Stock Options (right to buy)

    2024-06-17+40,00040,000 total
    Exercise: $0.20Exp: 2034-06-17Common stock (40,000 underlying)
Footnotes (2)
  • [F1]Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on June 17, 2024 (the "Grant Date"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
  • [F2]Pursuant to the Issuer's 2023 Plan, on the Grant Date, the Reporting Person was granted 60,000 Options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 5/13/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.

Documents

3 files
  • 4
    ownership.xmlPrimary
  • EX-24
  • GRAPHIC
    ex24_001.jpg